NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+

PURPOSE: Adjuvant trastuzumab reduces invasive breast cancer (IBC) recurrence and risk for death in patients with HER2-amplified or overexpressing IBC. A subset of patients in the landmark trastuzumab adjuvant trials who originally tested HER2-positive but were HER2-negative by central HER2 testing...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Oncol
Egile Nagusiak: Fehrenbacher, Louis, Cecchini, Reena S., Geyer Jr, Charles E., Rastogi, Priya, Costantino, Joseph P., Atkins, James N., Crown, John P., Polikoff, Jonathan, Boileau, Jean-Francois, Provencher, Louise, Stokoe, Christopher, Moore, Timothy D., Robidoux, André, Flynn, Patrick J., Borges, Virginia F., Albain, Kathy S., Swain, Sandra M., Paik, Soonmyung, Mamounas, Eleftherios P., Wolmark, Norman
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2020
Gaiak:
ORIGINAL REPORTS
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7007289/
https://ncbi.nlm.nih.gov/pubmed/31821109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01455
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak